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Glutathione-S-Transferase P1 Isoenzyme Polymorphisms,
Platinum-Based Chemotherapy, and
Non-small Cell Lung Cancer
Richard Booten, MB ChB, MRCP,*† Tim Ward, PhD,† Jim Heighway, PhD,§ Linda Ashcroft, BSc,*
Julie Morris, PhD,‡, and Nicholas Thatcher, PhD, FRCP*‡
Background: Polymorphisms within the P1 isoenzyme of GST
(GSTP1) are associated with alterations in enzyme activity and may
change sensitivity to platinum-based chemotherapy. We investigated
the relationship between exon 5 and exon 6 GSTP1 gene polymor-
phisms and treatment response, hematological, and nonhematologi-
cal toxicity and overall survival for patients receiving platinum-
based chemotherapy for advanced non-small cell lung cancer
(NSCLC).
Methods: Between 2001 and 2002, 108 patients with chemothera-
py-naı¨ve advanced NSCLC were recruited. Associations between
the GSTP1 polymorphisms (Ile105Val, Thr110Ser, Ala114Val, and
Asp 147Tyr) and GSTP1*A, *B, and *C haplotypes and treatment
response and toxicity were evaluated using the Pearson 2 and
Kruskal-Wallis tests, respectively. Associations with survival were
compared using Kaplan-Meier survival curves and Cox proportional
hazard ratios.
Results: No significant associations were noted between GSTP1
polymorphisms and treatment response or survival. Significantly
less neutropenic toxicity was demonstrated for patients possessing
the 105Val allele (p  0.020) or the GSTP1*B haplotype (p 
0.038). However, the variant allele GSTP1 105Val, and patients
possessing a GSTP1*B allele demonstrated notable trends toward
inferior response and survival.
Conclusions: GSTP1 haplotype can be used to stratify hematolog-
ical toxicity after platinum-based chemotherapy, but the lack of
significant associations with response or survival suggests that
GSTP1 polymorphisms may not be strong pharmacogenomic mark-
ers in this population. Additional large prospective studies incorpo-
rating the GSTP1 haplotype may clarify the reported discrepancies.
Key Words: GSTP1, Polymorphisms, Pharmacogenomics, Non-
small cell lung cancer.
(J Thorac Oncol. 2006;1: 679–683)
Worldwide, lung cancer is responsible for more than onemillion deaths per annum and is the leading cause of
cancer mortality.1 Palliative treatments for locally advanced
and metastatic non-small cell lung cancer (NSCLC), with
chemotherapy and/or radiotherapy, have become a standard
of care in this group but a therapeutic plateau has been
reached.2–4 In an attempt to advance the utility of current
regimens, a pharmacogenetic approach has been advocated.5,6
This concept “seeks to reduce the variation in how people
respond to medicines by tailoring therapy to individual ge-
netic make-up.”5 The identification of genetic markers that
are able to stratify patients more or less likely to benefit from
treatment may help to develop alternative strategies to im-
prove the outcomes of anticancer chemotherapy.
Platinum-based chemotherapy is the mainstay of
NSCLC treatment. Unfortunately, as many as 40% of patients
do not respond to first-line platinum-based chemotherapy,4
although much is known about the potential mechanisms of
platinum resistance.7–9 One such mechanism includes the
inactivation of intracellular cisplatin by glutathione.
Increased intracellular glutathione levels is associated
with previous exposure to platinum drugs and subsequent
platinum resistance,10–13 while down-regulating glutathione-
related enzymes or glutathione levels may improve cisplatin
sensitivity,12,14–17 by allowing aquated platinum species to
react with intracellular target molecules such that potentially
cytotoxic cisplatin-DNA monoadducts may convert to intras-
trand crosslinks.18 Increased expression of glutathione-S-trans-
ferase P1 isoenzyme (GSTP1), one of five glutathione-S-trans-
ferase isoenzymes, has been demonstrated to increase
intracellular glutathione and increase the proportion of GSH-Pt
adduct19 and to alter the response of patients undergoing plati-
num-based chemotherapy in a variety of solid tumors.20–24
Consequently, we sought to identify whether nonsyn-
onymous polymorphisms at a number of loci within GSTP1
affected toxicity or response to chemotherapy and survival in
patients with advanced NSCLC receiving platinum-based
chemotherapy as part of a phase III randomized trial.
PATIENTS AND METHODS
Patient Selection
Between June 2001 and November 2002, 433 patients
participated in a randomized phase III trial of docetaxel/
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carboplatin versus mitomycin, ifosfamide, cisplatin (MIC) or
mitomycin, vinblastine, cisplatin (MVP) in advanced NSCLC
from 16 institutions across the United Kingdom. Patients
recruited from two hospitals in South Manchester, UK
(Wythenshawe and Christie Hospitals) provided additional
informed consent for genotyping from whole blood. Patients
consenting to this represent the genotype cohort reported
herein. The local research and ethics committee approved the
study. The age, stage of disease, histology, and Eastern
Cooperative Group (ECOG) performance status were ob-
tained at study entry. Follow-up information, treatment re-
sponse, and survival were derived from the clinical trials
database at the Christie Hospital.
All patients enrolled in the study had pathologically
confirmed stage III-IV chemotherapy-naı¨ve NSCLC with an
ECOG performance status of 0-2 and received either do-
cetaxel 75 mg/m2 and carboplatin AUC 6 every 3 weeks or
mitomycin C 6 mg/m2, cisplatin 50 mg/m2, and vinblastine 6
mg/m2 or ifosfamide 3 g/m2 every 3 weeks to a maximum of
four cycles. Tumors were required to be measurable in at
least one dimension using the Response Evaluation Criteria in
Solid Tumors.25 Briefly, responses were determined in rela-
tion to the change in the sum of long-axis dimensions (LD)
for all target lesions between baseline and 4 weeks after
completion of chemotherapy. A complete response (CR) was
identified if no residual disease was evident, a partial re-
sponse (PR) if there was 30% reduction in the sum LD,
progressive disease (PD) if 20% increase in the sum LD,
and stable disease (SD) if criteria not met for CR, PR, and
PD. Responses were determined at the end of chemotherapy
by trial investigators without previous knowledge of clinical
outcome. Toxicity was assessed using the National Cancer
Institutes Common Toxicity Criteria (Version 2.0, 1/30/98)
and maximum toxicity recorded for each cycle of chemother-
apy administered.
DNA Extraction and Genotyping
Peripheral blood was drawn following randomization
and enrollment into the chemotherapy trial, and DNA was
extracted from these samples using the QIAamp Blood DNA
Midi Kit (Qiagen, Crawley, UK) and 2 ml of whole blood
according to manufacturer’s instructions. The known nonsyn-
onymous polymorphisms of exons 5 and 6 of GSTP1 (GSTP1
Ile105Val, Thr110Ser, Ala114Val, and Asp 147Tyr) were
determined using two independent runs of polymerase chain
reaction and direct sequencing followed by data analysis
using PhredPhrap, PolyPhred, and Consed software packag-
es.26–29 If both sequencing reactions were in agreement, the
genotype was considered robust. Haplotypes were deter-
mined according to Ishimoto and Ali-Osman30 and were as
follows: *A  105Ile/114Ala, *B  105Val/114Ala, *C 
105Val/114Val. Polymerase chain reaction oligonucleotides
were obtained from MWG Biotech (Milton Keynes, UK)
after a BLASTN search to ensure 100% sequence homology
with the gene of interest (accession number GSTP1-
AY324387). Oligonucleotide sequences and annealing tem-
peratures are listed in Table 1 and reactions performed for 38
polymerase chain reaction cycles.
RESULTS
Trial Demographics and Genetic Frequencies
Among the 179 patients who were randomized to che-
motherapy, 108 patients provided whole blood for genotyp-
ing (genotype cohort). No statistically significant differences
in age, sex, histology, stage, and performance status were
demonstrated between the chemotherapy arms and therefore
the genotype cohort was analyzed as a single group.
The genotype cohort included 74 (68.5%) males and 34
(31.5%) females with a median age 62.5 years (range, 35–80
years). The median overall survival time was 282 days (95%
confidence interval [CI]: 221–343 days). Fifty-two percent
(55/108) of the study participants died of disease during the
study period. Of the 108 patients, clinical response and
GSTP1 genotype could be determined for 88 (81%) and 90
(83%) patients with exon 5 and exon 6 GSTP1 genotypes,
respectively. The genotype and allele frequencies are listed in
Table 2. The variant allele of the GSTP1 110 and 147
TABLE 1. Polymerase Chain Reaction and Sequencing Primers for XPD and GSTP1
Polymorphisms
Polymorphism Primer sequences Tm
GSTP1 Ile105Val Exon5 F/S TGATCAGGCGCCCAGTCA 52
Thr110Ser R AAGAAGCCCCTTTCTTTGTTC
Ala114Val Exon6 F/S GAGCAAGCAGAGGAGAATCTG 57
Asp147Tyr R ACAAATGGCTCACACCTGTGT
F, 5= to 3= primer; R, 3= to 5= primer, S, sequencing primer.
TABLE 2. Genotype Distributions of the GSTP1 Gene in
Patients with Advanced Non-small Cell Lung Cancer
Genotype
Ile105Val
A¡G
(n  96)
Ala114Val
C¡T
(n  98)
Wild type AA 44.8 CC 87.8
Heterozygote AG 38.5 CT 12.2
Homozygous variant GG 16.7 TT 0
Allele frequency A 0.640 C 0.939
G 0.360 T 0.061
Genotypes were found to be in Hardy-Weinberg equilibrium with no significant
differences between observed and expected frequencies (2 test, p  0.05).
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polymorphisms were not detected in this patient group and
were not subject to further evaluation.
Tumor Response
For patients receiving chemotherapy, there was no
statistically significant difference in response to chemother-
apy between the two arms of chemotherapy. Consequently,
an objective response was documented in 30.5%, stable
disease in 28.2% and progressive disease in 29.2%.
No significant relationships were demonstrated be-
tween the GSTP1 105 or 114 variant allele according to
response to platinum-based chemotherapy (p  0.93 and p 
0.54, respectively). Similarly, response to chemotherapy was
not significantly associated with GSTP1 haplotype (p 0.82)
(Table 3). However, patients possessing one or more *B
allele exhibited an inferior tumor response compared to
patients who did not possess a *B allele.
Survival
No statistically significant differences in survival were
seen between the two chemotherapy arms in the genotype
cohort. Stage of disease was significantly associated with
survival (p  0.024) but age, histology, performance status,
and sex demonstrated no association.
For GSTP1 genotypes (Table 4), no significant differ-
ence in median survival was demonstrated for the GSTP1 105
or 114 polymorphic loci. However, the variant exon 6 geno-
type demonstrated greater median survival (Figure 1) and was
associated with a reduction in hazard ratio of death of 0.56.
GSTP1 haplotype demonstrated no significant relation-
ship with survival after platinum-based chemotherapy, but
possession of one or more GSTP1*B allele was associated
with a nonsignificant 22% increased risk of death.
Toxicity
No significant difference in grade of toxicity for hemo-
globin level or total white cell count was evident for GSTP1
genotype/haplotype. However, significant differences in
grade of neutropenia were seen for patients according to
GSTP1 105 and GSTP1 haplotypes such that the rate of
high-grade neutropenia was significantly decreased by the
105 variant allele and by the GSTP1*B allele (Table 5).
For nonhematological toxicity, no significant associa-
tions with the GSTP1 114 allele were demonstrated, although
for GSTP1 105, a significantly greater proportion of patients
TABLE 3. GSTP1 Genotype and Tumor Response
Genotype ORR SD PD
GSTP1 105 (n  86, p  0.93)
Wild-type Ile/Ile (n  38) 34.2 31.6 34.2
Heterozygote Ile/Val (n  32) 37.5 28.1 34.4
Variant Val/Val (n  16) 25 37.5 37.5
GSTP1 114 (n  89, p  0.54)
Wild-type Ala/Ala (n  77) 32.5 33.8 33.8
Heterozygote Ala/Val (n  12) 45.5 18.2 36.4
Variant Val/Val (n  0) 0 0 0
GSTP1 haplotypes (p  0.82)
Ile105Ile/Ala114Ala AA (n  38) 32.0 31.6 34.2
Ile105Val/Ala114Ala AB (n  25) 28.6 36.0 32.0
Val105Val/Ala114Ala BB (n  13) 23.1 38.5 38.5
Ile105Val/Ala114Val AC (n  7) 57.1 0 42.9
Val105Val/Ala114Val BC (n  3) 33.3 33.3 33.3
GSTP1 by B haplotype (p  0.56)
B haplotypes (n  41) 29.3 36.6 34.1
Non-B haplotypes (n  45) 37.8 26.7 35.6
GSTP1 haplotypes: *A, 105Ile/114Ala; *B, 105Val/114Ala; *C, 105Val/114Val.
ORR, objective response rate; SD, stable disease; PD, progressive disease.
TABLE 4. GSTP1 Genotype and Survival
Median survival (mo) 95% CI p HR 95% CI
Genotype cohort 9.3 7.3–11.3
GSTP1 105
Wild type 9.3 7.5–11.0 0.72 1.0
Heterozygote 10.8 5.6–15.9 0.83 0.44–1.58
Variant 7.7 6.5–8.9 1.14 0.52–2.50
GSTP1 114
Wild type 9.2 7.0–11.3 0.18 1.0
Heterozygote 11.9 8.6–15.1 0.56 0.24–1.33
Variant — — — —
GSTP1 haplotypes
Ile105Ile/Ala114Ala AA (n  38) 9.3 7.5–11.0 0.70
Ile105Val/Ala114Ala AB (n  25) 8.0 5.5–10.5
Val105Val/Ala114Ala BB (n  13) 8.1 1.6–14.6
Ile105Val/Ala114Val AC (n  7) 11.9 2.6–21.2
Val105Val/Ala114Val BC (n  3) — —
B haplotypes (AB, BB, BC) 8.0 6.7–9.3 0.49 1.22 0.69–2.13
Non-B haplotypes (AA, AC) 10.8 8.6–12.8 1.0
CI, confidence interval; HR, hazard ratio.
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of homozygous variant genotype possessed grade 0 mucositis
compared to the other genotypes (p  0.021).
DISCUSSION
In view of the current therapeutic plateau in treatment
for advanced NSCLC, we sought to evaluate whether non-
synonymous polymorphisms in GSTP1 were associated with
toxicity or response to chemotherapy or influenced survival
after platinum-based chemotherapy.
GSTs play an important role in detoxification by cata-
lyzing the conjugation of many compounds with reduced
glutathione. Four main classes exist and include the GSTP1
isoenzyme that is expressed at particularly high levels in
normal lung tissue, in lung cancer, and in malignant tissue
relative to matched normal tissues.31 Four nonsynonymous
polymorphic variants are reported for GSTP1 (http://
www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId2950), al-
though in our population of patients with advanced NSCLC,
only the codon 105 and 114 polymorphisms were present. In
1998, Watson et al.32 considered these polymorphisms in
surgically resected normal lung tissue and their effect on the
glutathione-conjugating ability of GSTP1. Significant differ-
ences in conjugating ability were found for Ile105Val, with
wild-type 105Ile genotypes being most protective and variant
105Val genotypes the least protective (p  0.05). However,
no relationship for the Ala114Val polymorphism and altered
enzyme activity was elicited. In vivo data are in keeping with
this observation, as patients who possess the 105Val variant
demonstrate elevated DNA adducts (45% higher) in normal
breast tissue compared to wild-type genotypes.33 Further
supportive data come from Stoehlmacher et al.,34,35 in a study
of 106 colorectal cancer patients receiving oxaliplatin, who
noted significantly improved survival for variant genotypes
(Val105Val) compared to wild-type patients. However, sig-
nificance was lost after stratification for performance status.
Furthermore, in a study of more than 400 patients with
advanced NSCLC, Lu et al.36 demonstrated that variant exon
6 genotypes (114Val), but not variant exon 5 genotypes
(105Val), were associated with increased survival and a
reduced adjusted hazard ratio for death of 0.75. Our results
did not produce statistically significant results for the GSTP1
105 or 114 loci according to response or survival data but are
in keeping with these observations. We have also extended
these observations to include an analysis of GSTP1 haplo-
types that have variable cytoprotective activities, GSTP1*A
being least protective and GSTP1*C most protective in re-
sponse to platinum drug administration.30 GSTP1*A is the
most common allele in our population (0.628), with allele
TABLE 5. Common Toxicity Criteria for Neutropenia, GSTP1 Polymorphisms, and Platinum-Based
Chemotherapy
CTC Grade for Neutropenia
Genotype 0 1 2 3 4 p
GSTP1 105 (n  93)
Wild type 14.6 12.2 0 7.3 65.9 0.020
Heterozygote 5.4 2.7 8.1 21.6 62.2
Variant 6.7 6.7 26.7 13.3 46.7
GSTP1 114 (n  95)
Wild type 9.5 7.1 7.1 13.3 63.1 0.98
Heterozygote/variant 9.1 9.1 9.1 18.2 54.5
GSTP1 haplotype (n  93)
AA 14.6 12.2 0 7.3 65.9 0.015
AB 3.4 3.4 6.9 24.1 62.1
AC 12.5 0 12.5 12.5 62.5
BB 7.7 0 30.8 7.7 53.8
BC 0 50 0 50 0
AB, BB, BC 4.5 4.5 13.6 20.6 56.8 0.038
AA, AC 14.3 10.2 2.0 8.2 65.3
FIGURE 1. Kaplan-Meier survival curves for patients receiv-
ing platinum-based chemotherapy by GSTP1 114 genotype.
CI, confidence interval.
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frequencies for GSTP1*B and C of 0.314 and 0.058, respec-
tively. Our data suggest that the GSTP1*B allele is associated
with a reduced response to platinum drugs and a poorer
survival and are in keeping with the greater protective activity
reported in vitro compared to GSTP1*A. In addition, and
further supporting the protective role of the GSTP1*B hap-
lotype, are the significant differences in hematological toxic-
ity demonstrated between patients who possess at least one
copy of the GSTP1*B allele compared to patients without.
This report represents one of the largest series in
advanced NSCLC evaluating a pharmacogenomic approach
to therapy. Polymorphisms in GSTP1 do not appear to be
strong biomarkers for the predictive prescription of platinum-
based chemotherapy, but our data suggest that differential
GSTP1 enzyme activity can be identified by GSTP1 haplo-
type but requires confirmation in a larger sample size. Well-
designed prospective, randomized clinical trials using these
biomarkers should clarify the reported discrepancies between
the published studies and delineate their place in clinical
practice.
REFERENCES
1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global
and regional estimates of cancer mortality and incidence by site: II.
Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
2. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of
paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the
treatment of patients with advanced non-small-cell lung cancer: a South-
west Oncology Group trial. J Clin Oncol 2001;19:3210–3218.
3. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial
comparing three platinum-based doublets in advanced non-small-cell
lung cancer. J Clin Oncol 2002;20:4285–4291.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four che-
motherapy regimens for advanced non-small-cell lung cancer. N Engl
J Med 2002;346:92–98.
5. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic.
Nat Rev Genet 2003;4:937–947.
6. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90:
8–11.
7. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor
platinum drugs. Drug Resist Update 2002;5:147–161.
8. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin.
Mutat Res 2001;478:23–43.
9. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular
proteins. Mutat Res 2001;478:1–21.
10. Newkirk K, Heffern J, Sloman-Moll E, et al. Glutathione content but not
gamma glutamyl cysteine synthetase mRNA expression predicts cispla-
tin resistance in head and neck cancer cell lines. Cancer Chemother
Pharmacol 1997;40:75–80.
11. Juvekar AS, Adwankar MK, Tongaonkar HB. Effect of cisplatin-based
chemotherapy on emergence of cisplatin resistance, and its correlation
with intracellular glutathione levels and accumulation of p53 protein in
human ovarian cancer. Cancer Biother Radiopharm 2000;15:295–300.
12. Ikeda K, Miura K, Himeno S, Imura N, Naganuma A. Glutathione
content is correlated with the sensitivity of lines of PC12 cells to
cisplatin without a corresponding change in the accumulation of plati-
num. Mol Cell Biochem 2001;219:51–56.
13. Lewandowicz GM, Britt P, Elgie AW, et al. Cellular glutathione content,
in vitro chemoresponse, and the effect of BSO modulation in samples
derived from patients with advanced ovarian cancer. Gynecol Oncol
2002;85:298–304.
14. Ogawa J, Iwazaki M, Inoue H, Koide S, Shohtsu A. Immunohistochem-
ical study of glutathione-related enzymes and proliferative antigens in
lung cancer. Relation to cisplatin sensitivity. Cancer 1993;71:2204–
2209.
15. Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione
S-transferase (GST)-pi antisense complementary DNA increases the
sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melpha-
lan, and etoposide. Cancer Res 1996;56:3577–3582.
16. Nagata J, Kijima H, Hatanaka H, et al. Reversal of cisplatin and
multidrug resistance by ribozyme-mediated glutathione suppression.
Biochem Biophys Res Commun 2001;286:406–413.
17. Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. Significance of Nuclear
Glutathione S-Transferase pi in Resistance to Anti-cancer Drugs. Jpn J
Cancer Res. 2002;93:1047–56.
18. Eastman A. Cross-linking of glutathione to DNA by cancer chemother-
apeutic platinum coordination complexes. Chem Biol Interact 1987;61:
241–248.
19. Goto S, Iida T, Cho S, et al. Overexpression of glutathione S-transferase
pi enhances the adduct formation of cisplatin with glutathione in human
cancer cells. Free Radic Res 1999;31:549–558.
20. Hamada S, Kamada K, Furumoto H, Hirao T, Aono T. Expression of
glutathione S-transferase-pi in human ovarian cancer as an indicator of
resistance to chemotherapy. Gynecol Oncol 1994;52:313–319.
21. Nishimura T, Newkirk K, Sessions RB, et al. Immunohistochemical
staining for glutathione S-transferase predicts response to platinum-
based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:
1859–1865.
22. Bai F, Nakanishi Y, Kawasaki M, et al. Immunohistochemical expres-
sion of glutathione S-transferase-Pi can predict chemotherapy response
in patients with nonsmall cell lung carcinoma. Cancer 1996;78:416–421.
23. Li L, Yao D, Chen X. [The expression of glutathione S-transferase pi in
human ovarian cancer as an indicator of resistance to chemotherapy].
Zhonghua Fu Chan Ke Za Zhi 1998;33:95–97.
24. Arai T, Yasuda Y, Takaya T, et al. Immunohistochemical expression of
glutathione transferase-pi in untreated primary non-small-cell lung can-
cer. Cancer Detect Prev 2000;24:252–257.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to
Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst
2000;92:205–216.
26. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detec-
tion and genotyping of single nucleotide substitutions using fluores-
cence-based resequencing. Nucleic Acids Res 1997;25:2745–2751.
27. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence
finishing. Genome Res 1998;8:195–202.
28. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated
sequencer traces using Phred. I. Accuracy assessment. Genome Res
1998;8:175–185.
29. Ewing B, Green P. Base-calling of automated sequencer traces using
Phred. II. Error probabilities. Genome Res 1998;8:186–194.
30. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione
S-transferase P1 gene confer differential cytoprotection against antican-
cer agents in Escherichia coli. Pharmacogenetics 2002;12:543–553.
31. Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic
glutathione-S-transferase and P-glycoprotein genes in human tissues and
tumors. Cancer Res 1989;49:1422–1428.
32. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human
glutathione S-transferase P1 polymorphisms: relationship to lung tissue
enzyme activity and population frequency distribution. Carcinogenesis.
1998;19:275–280.
33. Brockstedt U, Krajinovic M, Richer C, et al. Analyses of bulky DNA
adduct levels in human breast tissue and genetic polymorphisms of
cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxi-
doreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res
2002;516:41-47.
34. Stoehlmacher J, Park DJ, Zhang W, et al. Association between gluta-
thione S-transferase P1, T1, and M1 genetic polymorphism and survival
of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;
94:936–942.
35. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of
genomic polymorphisms: prediction of clinical outcome to 5-FU/oxali-
platin combination chemotherapy in refractory colorectal cancer. Br J
Cancer 2004;91:344–54.
36. Lu C, Spitz MR, Zhao H, et al. Association between glutathione
S-transferase pi polymorphisms and survival in patients with advanced
nonsmall cell lung carcinoma. Cancer 2006;106:441–447.
Journal of Thoracic Oncology • Volume 1, Number 7, September 2006 GSTP1, Platinum Chemotherapy and NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 683
